NCT02428985View on ClinicalTrials.gov

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

CompletedOBSERVATIONAL
Enrollment

882

Participants

Timeline

Start Date

June 29, 2015

Primary Completion Date

April 17, 2023

Study Completion Date

September 20, 2023

Conditions
Hypertension, Pulmonary
Interventions
DRUG

Riociguat (ADEMPAS, BAY63-2521)

The treatment of Riociguat should comply with the local product information

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY